Does the media prefer CRNX or WVE?

In the previous week, Crinetics Pharmaceuticals had 48 more articles in the media than WAVE Life Sciences. MarketBeat recorded 51 mentions for Crinetics Pharmaceuticals and 3 mentions for WAVE Life Sciences. WAVE Life Sciences' average media sentiment score of 0.63 beat Crinetics Pharmaceuticals' score of 0.16 indicating that WAVE Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Crinetics Pharmaceuticals 12 Very Positive mention(s) 12 Positive mention(s) 9 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral WAVE Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ACAD or WVE?

In the previous week, ACADIA Pharmaceuticals had 7 more articles in the media than WAVE Life Sciences. MarketBeat recorded 10 mentions for ACADIA Pharmaceuticals and 3 mentions for WAVE Life Sciences. ACADIA Pharmaceuticals' average media sentiment score of 0.94 beat WAVE Life Sciences' score of 0.63 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ACADIA Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive WAVE Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer VKTX or WVE?

In the previous week, Viking Therapeutics had 8 more articles in the media than WAVE Life Sciences. MarketBeat recorded 11 mentions for Viking Therapeutics and 3 mentions for WAVE Life Sciences. Viking Therapeutics' average media sentiment score of 0.68 beat WAVE Life Sciences' score of 0.63 indicating that Viking Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viking Therapeutics 5 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive WAVE Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer TNGX or WVE?

In the previous week, Tango Therapeutics had 1 more articles in the media than WAVE Life Sciences. MarketBeat recorded 4 mentions for Tango Therapeutics and 3 mentions for WAVE Life Sciences. Tango Therapeutics' average media sentiment score of 1.57 beat WAVE Life Sciences' score of 0.63 indicating that Tango Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tango Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive WAVE Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer EWTX or WVE?

In the previous week, Edgewise Therapeutics had 1 more articles in the media than WAVE Life Sciences. MarketBeat recorded 4 mentions for Edgewise Therapeutics and 3 mentions for WAVE Life Sciences. Edgewise Therapeutics' average media sentiment score of 0.73 beat WAVE Life Sciences' score of 0.63 indicating that Edgewise Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edgewise Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive WAVE Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

WAVE Life Sciences (WVE) Competitors

$5.95 -0.30 (-4.80%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$6.05 +0.10 (+1.68%)

As of 07/13/2026 07:44 PM Eastern

Compare

WVE vs. CRNX, ACAD, VKTX, TNGX, and EWTX

Should you buy WAVE Life Sciences stock or one of its competitors? MarketBeat compares WAVE Life Sciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with WAVE Life Sciences include Crinetics Pharmaceuticals (CRNX), ACADIA Pharmaceuticals (ACAD), Viking Therapeutics (VKTX), Tango Therapeutics (TNGX), and Edgewise Therapeutics (EWTX). These companies are all part of the "pharmaceutical products" industry.

How does WAVE Life Sciences compare to Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals (NASDAQ:CRNX) and WAVE Life Sciences (NASDAQ:WVE) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk.

WAVE Life Sciences has a net margin of -255.70% compared to Crinetics Pharmaceuticals' net margin of -2,747.18%. Crinetics Pharmaceuticals' return on equity of -43.96% beat WAVE Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Crinetics Pharmaceuticals	-2,747.18%	-43.96%	-39.61%
WAVE Life Sciences	-255.70%	-56.76%	-42.80%

98.5% of Crinetics Pharmaceuticals shares are owned by institutional investors. Comparatively, 89.7% of WAVE Life Sciences shares are owned by institutional investors. 3.8% of Crinetics Pharmaceuticals shares are owned by insiders. Comparatively, 24.3% of WAVE Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

WAVE Life Sciences has higher revenue and earnings than Crinetics Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than WAVE Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crinetics Pharmaceuticals	$7.70M	1,145.74	-$465.32M	-$5.13	N/A
WAVE Life Sciences	$42.73M	26.79	-$204.38M	-$1.06	N/A

Crinetics Pharmaceuticals has a beta of 0.23, indicating that its stock price is 77% less volatile than the broader market. Comparatively, WAVE Life Sciences has a beta of -1.29, indicating that its stock price is 229% less volatile than the broader market.

Crinetics Pharmaceuticals presently has a consensus price target of $78.27, suggesting a potential downside of 6.45%. WAVE Life Sciences has a consensus price target of $26.41, suggesting a potential upside of 343.90%. Given WAVE Life Sciences' stronger consensus rating and higher probable upside, analysts plainly believe WAVE Life Sciences is more favorable than Crinetics Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crinetics Pharmaceuticals	1 Sell rating(s)	10 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.29
WAVE Life Sciences	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.87

In the previous week, Crinetics Pharmaceuticals had 48 more articles in the media than WAVE Life Sciences. MarketBeat recorded 51 mentions for Crinetics Pharmaceuticals and 3 mentions for WAVE Life Sciences. WAVE Life Sciences' average media sentiment score of 0.63 beat Crinetics Pharmaceuticals' score of 0.16 indicating that WAVE Life Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Crinetics Pharmaceuticals	12 Very Positive mention(s)	12 Positive mention(s)	9 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
WAVE Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

WAVE Life Sciences beats Crinetics Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does WAVE Life Sciences compare to ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals (NASDAQ:ACAD) and WAVE Life Sciences (NASDAQ:WVE) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends, valuation and media sentiment.

ACADIA Pharmaceuticals has a beta of 0.8, suggesting that its stock price is 20% less volatile than the broader market. Comparatively, WAVE Life Sciences has a beta of -1.29, suggesting that its stock price is 229% less volatile than the broader market.

ACADIA Pharmaceuticals has higher revenue and earnings than WAVE Life Sciences. WAVE Life Sciences is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ACADIA Pharmaceuticals	$1.07B	4.08	$391M	$2.20	11.59
WAVE Life Sciences	$42.73M	26.79	-$204.38M	-$1.06	N/A

In the previous week, ACADIA Pharmaceuticals had 7 more articles in the media than WAVE Life Sciences. MarketBeat recorded 10 mentions for ACADIA Pharmaceuticals and 3 mentions for WAVE Life Sciences. ACADIA Pharmaceuticals' average media sentiment score of 0.94 beat WAVE Life Sciences' score of 0.63 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ACADIA Pharmaceuticals	5 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
WAVE Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ACADIA Pharmaceuticals has a net margin of 34.30% compared to WAVE Life Sciences' net margin of -255.70%. ACADIA Pharmaceuticals' return on equity of 9.61% beat WAVE Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ACADIA Pharmaceuticals	34.30%	9.61%	7.07%
WAVE Life Sciences	-255.70%	-56.76%	-42.80%

96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. Comparatively, 89.7% of WAVE Life Sciences shares are owned by institutional investors. 26.2% of ACADIA Pharmaceuticals shares are owned by company insiders. Comparatively, 24.3% of WAVE Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

ACADIA Pharmaceuticals presently has a consensus target price of $32.94, suggesting a potential upside of 29.18%. WAVE Life Sciences has a consensus target price of $26.41, suggesting a potential upside of 343.90%. Given WAVE Life Sciences' stronger consensus rating and higher probable upside, analysts plainly believe WAVE Life Sciences is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ACADIA Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.65
WAVE Life Sciences	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.87

Summary

ACADIA Pharmaceuticals beats WAVE Life Sciences on 12 of the 16 factors compared between the two stocks.

How does WAVE Life Sciences compare to Viking Therapeutics?

Viking Therapeutics (NASDAQ:VKTX) and WAVE Life Sciences (NASDAQ:WVE) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, media sentiment, risk, profitability, valuation and earnings.

WAVE Life Sciences has higher revenue and earnings than Viking Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than WAVE Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.14	N/A
WAVE Life Sciences	$42.73M	26.79	-$204.38M	-$1.06	N/A

76.0% of Viking Therapeutics shares are owned by institutional investors. Comparatively, 89.7% of WAVE Life Sciences shares are owned by institutional investors. 5.3% of Viking Therapeutics shares are owned by company insiders. Comparatively, 24.3% of WAVE Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Viking Therapeutics has a net margin of 0.00% compared to WAVE Life Sciences' net margin of -255.70%. WAVE Life Sciences' return on equity of -56.76% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viking Therapeutics	N/A	-71.31%	-65.35%
WAVE Life Sciences	-255.70%	-56.76%	-42.80%

Viking Therapeutics presently has a consensus target price of $93.60, suggesting a potential upside of 145.54%. WAVE Life Sciences has a consensus target price of $26.41, suggesting a potential upside of 343.90%. Given WAVE Life Sciences' stronger consensus rating and higher possible upside, analysts clearly believe WAVE Life Sciences is more favorable than Viking Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viking Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.79
WAVE Life Sciences	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.87

Viking Therapeutics has a beta of 0.66, meaning that its stock price is 34% less volatile than the broader market. Comparatively, WAVE Life Sciences has a beta of -1.29, meaning that its stock price is 229% less volatile than the broader market.

In the previous week, Viking Therapeutics had 8 more articles in the media than WAVE Life Sciences. MarketBeat recorded 11 mentions for Viking Therapeutics and 3 mentions for WAVE Life Sciences. Viking Therapeutics' average media sentiment score of 0.68 beat WAVE Life Sciences' score of 0.63 indicating that Viking Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viking Therapeutics	5 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
WAVE Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

WAVE Life Sciences beats Viking Therapeutics on 11 of the 16 factors compared between the two stocks.

How does WAVE Life Sciences compare to Tango Therapeutics?

Tango Therapeutics (NASDAQ:TNGX) and WAVE Life Sciences (NASDAQ:WVE) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings, media sentiment and valuation.

In the previous week, Tango Therapeutics had 1 more articles in the media than WAVE Life Sciences. MarketBeat recorded 4 mentions for Tango Therapeutics and 3 mentions for WAVE Life Sciences. Tango Therapeutics' average media sentiment score of 1.57 beat WAVE Life Sciences' score of 0.63 indicating that Tango Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tango Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
WAVE Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tango Therapeutics has higher revenue and earnings than WAVE Life Sciences. Tango Therapeutics is trading at a lower price-to-earnings ratio than WAVE Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tango Therapeutics	$62.38M	65.76	-$101.59M	-$0.83	N/A
WAVE Life Sciences	$42.73M	26.79	-$204.38M	-$1.06	N/A

Tango Therapeutics has a net margin of 0.00% compared to WAVE Life Sciences' net margin of -255.70%. Tango Therapeutics' return on equity of -41.54% beat WAVE Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tango Therapeutics	N/A	-41.54%	-33.44%
WAVE Life Sciences	-255.70%	-56.76%	-42.80%

79.0% of Tango Therapeutics shares are held by institutional investors. Comparatively, 89.7% of WAVE Life Sciences shares are held by institutional investors. 6.5% of Tango Therapeutics shares are held by insiders. Comparatively, 24.3% of WAVE Life Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Tango Therapeutics has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market. Comparatively, WAVE Life Sciences has a beta of -1.29, indicating that its share price is 229% less volatile than the broader market.

Tango Therapeutics presently has a consensus price target of $41.50, suggesting a potential upside of 46.33%. WAVE Life Sciences has a consensus price target of $26.41, suggesting a potential upside of 343.90%. Given WAVE Life Sciences' stronger consensus rating and higher probable upside, analysts clearly believe WAVE Life Sciences is more favorable than Tango Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73
WAVE Life Sciences	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.87

Summary

Tango Therapeutics beats WAVE Life Sciences on 10 of the 16 factors compared between the two stocks.

How does WAVE Life Sciences compare to Edgewise Therapeutics?

Edgewise Therapeutics (NASDAQ:EWTX) and WAVE Life Sciences (NASDAQ:WVE) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings, media sentiment and profitability.

Edgewise Therapeutics currently has a consensus target price of $47.92, suggesting a potential upside of 16.11%. WAVE Life Sciences has a consensus target price of $26.41, suggesting a potential upside of 343.90%. Given WAVE Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe WAVE Life Sciences is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
WAVE Life Sciences	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.87

89.7% of WAVE Life Sciences shares are held by institutional investors. 21.3% of Edgewise Therapeutics shares are held by insiders. Comparatively, 24.3% of WAVE Life Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Edgewise Therapeutics had 1 more articles in the media than WAVE Life Sciences. MarketBeat recorded 4 mentions for Edgewise Therapeutics and 3 mentions for WAVE Life Sciences. Edgewise Therapeutics' average media sentiment score of 0.73 beat WAVE Life Sciences' score of 0.63 indicating that Edgewise Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Edgewise Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
WAVE Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Edgewise Therapeutics has a beta of 0.27, suggesting that its stock price is 73% less volatile than the broader market. Comparatively, WAVE Life Sciences has a beta of -1.29, suggesting that its stock price is 229% less volatile than the broader market.

Edgewise Therapeutics has higher earnings, but lower revenue than WAVE Life Sciences. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than WAVE Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.66	N/A
WAVE Life Sciences	$42.73M	26.79	-$204.38M	-$1.06	N/A

Edgewise Therapeutics has a net margin of 0.00% compared to WAVE Life Sciences' net margin of -255.70%. Edgewise Therapeutics' return on equity of -32.55% beat WAVE Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edgewise Therapeutics	N/A	-32.55%	-31.04%
WAVE Life Sciences	-255.70%	-56.76%	-42.80%

Summary

Edgewise Therapeutics and WAVE Life Sciences tied by winning 8 of the 16 factors compared between the two stocks.

Get WAVE Life Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding WVE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

WVE vs. The Competition

Export

Metric	WAVE Life Sciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.20B	$3.71B	$7.05B	$12.61B
Dividend Yield	N/A	2.20%	2.68%	8.00%
P/E Ratio	-5.61	20.85	27.11	24.26
Price / Sales	26.79	314.01	587.92	117.88
Price / Cash	N/A	61.98	29.22	49.36
Price / Book	1.92	8.49	10.75	6.29
Net Income	-$204.38M	$23.83M	$3.58B	$330.66M
7 Day Performance	-6.74%	-3.56%	-2.06%	-1.32%
1 Month Performance	1.36%	6.31%	3.32%	-0.64%
1 Year Performance	-24.11%	48.30%	26.35%	19.08%

WAVE Life Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
WVE WAVE Life Sciences	2.758 of 5 stars	$5.95 -4.8%	$26.41 +343.9%	-22.7%	$1.20B	$42.73M	N/A	240
CRNX Crinetics Pharmaceuticals	1.4592 of 5 stars	$42.23 flat	$73.78 +74.7%	+162.0%	$4.45B	$7.70M	N/A	210	Analyst Upgrade
ACAD ACADIA Pharmaceuticals	4.8196 of 5 stars	$25.97 flat	$32.59 +25.5%	+21.5%	$4.45B	$1.07B	11.80	510
VKTX Viking Therapeutics	2.9651 of 5 stars	$37.44 flat	$93.60 +150.0%	+22.5%	$4.35B	N/A	N/A	20	Gap Down
TNGX Tango Therapeutics	2.9573 of 5 stars	$29.46 flat	$41.50 +40.9%	+378.2%	$4.26B	$62.38M	N/A	90	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:WVE) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

WAVE Life Sciences (WVE) Competitors

WVE vs. CRNX, ACAD, VKTX, TNGX, and EWTX

How does WAVE Life Sciences compare to Crinetics Pharmaceuticals?

Summary

How does WAVE Life Sciences compare to ACADIA Pharmaceuticals?

Summary

How does WAVE Life Sciences compare to Viking Therapeutics?

Summary

How does WAVE Life Sciences compare to Tango Therapeutics?

Summary

How does WAVE Life Sciences compare to Edgewise Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

WVE vs. The Competition

WAVE Life Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

WAVE Life Sciences (WVE) Competitors

WVE vs. CRNX, ACAD, VKTX, TNGX, and EWTX

How does WAVE Life Sciences compare to Crinetics Pharmaceuticals?

Is CRNX or WVE more profitable?

Do insiders and institutionals hold more shares of CRNX or WVE?

Which has higher valuation and earnings, CRNX or WVE?

Which has more volatility and risk, CRNX or WVE?

Do analysts recommend CRNX or WVE?

Does the media prefer CRNX or WVE?

Summary

How does WAVE Life Sciences compare to ACADIA Pharmaceuticals?

Which has more volatility & risk, ACAD or WVE?

Which has stronger earnings & valuation, ACAD or WVE?

Does the media prefer ACAD or WVE?

Is ACAD or WVE more profitable?

Do insiders & institutionals hold more shares of ACAD or WVE?

Do analysts rate ACAD or WVE?

Summary

How does WAVE Life Sciences compare to Viking Therapeutics?

Which has higher earnings & valuation, VKTX or WVE?

Do institutionals & insiders have more ownership in VKTX or WVE?

Is VKTX or WVE more profitable?

Do analysts prefer VKTX or WVE?

Which has more risk and volatility, VKTX or WVE?

Does the media prefer VKTX or WVE?

Summary

How does WAVE Life Sciences compare to Tango Therapeutics?

Does the media prefer TNGX or WVE?

Which has higher earnings and valuation, TNGX or WVE?

Is TNGX or WVE more profitable?

Do institutionals and insiders have more ownership in TNGX or WVE?

Which has more risk and volatility, TNGX or WVE?

Do analysts recommend TNGX or WVE?

Summary

How does WAVE Life Sciences compare to Edgewise Therapeutics?

Do analysts recommend EWTX or WVE?

Do insiders & institutionals have more ownership in EWTX or WVE?

Does the media prefer EWTX or WVE?

Which has more risk & volatility, EWTX or WVE?

Which has stronger valuation & earnings, EWTX or WVE?

Is EWTX or WVE more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

WVE vs. The Competition

WAVE Life Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools